Edition:
United States

Deena Beasley

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

Jun 11 2018

Biotech's Soon-Shiong hiring bankers for Nant cancer drug IPO

LOS ANGELES Billionaire Patrick Soon-Shiong plans to take an experimental cancer treatment company public this year and has begun hiring bankers, the biotechnology entrepreneur told Reuters.

Jun 04 2018

U.S. FDA wants to shorten new drug monopolies to cut costs

CHICAGO In an effort to increase competition and bring down prescription drug prices, FDA Commissioner Dr. Scott Gottlieb wants to speed approval times for rivals to promising new first-to-market medicines.

Jun 03 2018

FDA wants to shorten new drug monopolies to cut costs

CHICAGO In an effort to increase competition and bring down prescription drug prices, FDA Commissioner Dr. Scott Gottlieb wants to speed approval times for rivals to promising new first-to-market medicines.

Jun 03 2018

Merck's Keytruda extends lung cancer survival in two trials

CHICAGO Merck & Co's immunotherapy Keytruda improved survival as a stand-alone treatment for newly-diagnosed lung cancer patients and with chemotherapy for hard-to-treat squamous cell lung cancer, new data released on Sunday showed, further cementing the company's lead in the most lucrative oncology market.

Jun 03 2018

Merck's Keytruda shown to extend lung cancer survival in 2 trials

CHICAGO, June 3 New trial results show that Merck & Co's Keytruda improves survival as a stand-alone treatment for newly diagnosed lung cancer and in combination with chemotherapy for hard-to-treat squamous cell lung cancer.

Jun 02 2018

Roche drugs show limited benefit in lung, breast cancer trials

CHICAGO In a disappointment for Roche Holding AG , two of its oncology drugs provided only modest protection from disease progression in lung cancer and breast cancer, according to data from separate clinical trials presented on Saturday.

Jun 01 2018

Bluebird myeloma treatment delays cancer progression: trial

CHICAGO Patients with advanced multiple myeloma treated with bluebird bio's experimental immunotherapy lived for a median of nearly a year before their cancer worsened, according to data from a small study presented on Friday.

Jun 01 2018

Canada colon cancer drugs half the price, same survival as U.S.: study

CHICAGO Colon cancer drugs cost twice as much in the United States as in Canada, but added expense does not translate to longer survival, according to a study of insurance claims data from Washington state and neighboring British Columbia presented on Friday.

Jun 01 2018

Leading oncology group wary of Trump drug price proposals

CHICAGO A leading U.S. group of cancer doctors is wary of new Trump administration proposals for lowering drug prices, particularly if new negotiation tools are introduced that will mean the U.S. government no longer routinely pays for all cancer drugs in the Medicare health program for older people.

Jun 01 2018

Leading oncology group wary of Trump drug price proposals

CHICAGO America's leading group of cancer doctors is wary of new Trump administration proposals for lowering drug costs, warning that patients must not be barred from medicines that could help them.

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary